Recurrent Glioblastoma Clinical Trials 2023

What are the top hospitals conducting recurrent glioblastoma research?

In the battle against recurrent glioblastoma, several top hospitals are leading the charge in clinical trials. Boston's Dana-Farber Cancer Institute stands out with an impressive 11 ongoing trials focused on this aggressive brain tumor, alongside a remarkable track record of 65 completed studies dedicated to recurrent glioblastoma. Their groundbreaking research dates back to their first recorded trial in 1998. Meanwhile, Memorial Sloan Kettering Cancer Center in New york City is also making significant contributions with eight active trials and a history of 47 prior studies since their inaugural recurrent glioblastoma trial in 2002.

However, it's not just the East Coast that is pushing boundaries in this field. In St. Louis, Washington University School of Medicine boasts eight ongoing clinical trials for recurrent glioblastoma and has amassed a total of 49 previous studies conducted since recording their first trial for this condition back in 2006. Lenox Hill Brain Tumor Center, located right within New York City itself, may have fewer active trials with five but still plays an important role as they have contributed to fifteen previous investigations into treating recurrent glioblastoma since embarking on their initial study also starting from2006.

On the West Coast, we find another powerhouse institution at work: The University of California San Francisco (UCSF). With five current clinical trials targeting recurrent glioblastoma and twenty-five past endeavors under its belt dating back to their earliest recorded trial for this disease type launched around eighteen years ago during2004.

These hospitals represent beacons of hope for patients battling recurrence of this challenging brain tumor. Through cutting-edge research and innovative treatments offered by these renowned medical centers across different locations nationwide—be it Boston or New York City or even St.Louis or San Francisco—their collective efforts bring us ever closer to finding solutions that can potentially change lives affected by such devastating conditions

Which are the best cities for recurrent glioblastoma clinical trials?

When it comes to clinical trials for recurrent glioblastoma, several cities emerge as influential hubs of research. New york, with its 32 ongoing trials, investigates promising treatments like INO-5401, Pemigatinib, and combinations of RT plus TMZ and ENZ. Boston follows closely behind with 29 active studies exploring therapies such as Pembrolizumab and Olaparib. Saint Louis also contributes significantly with 21 ongoing trials examining Quality-of-Life Assessment, Olaparib, Radiation Therapy among other approaches. Finally, Los Angeles and Dallas both play essential roles in the pursuit of innovative treatments for recurrent glioblastoma through their respective active trials on various potential interventions. These cities collectively represent crucial centers where patients can access cutting-edge clinical trials in the fight against this challenging disease.

Which are the top treatments for recurrent glioblastoma being explored in clinical trials?

Clinical trials for recurrent glioblastoma are actively exploring various treatment options. Temozolomide, a well-established drug in the field since 2002, is leading with six active trials and an impressive track record of 218 all-time recurrent glioblastoma trials. Nivolumab, introduced in 2014, shows promise with three ongoing trials and involvement in 27 past studies. Radiation therapy remains a crucial contender, currently being investigated in three active clinical trials among a total of 48 recurrent glioblastoma studies to date. In addition, intra-arterial cetuximab and ibrutinib are also under investigation through two active trials each but have fewer past trial involvements compared to other treatments on this list. These innovative approaches offer hope for patients battling this aggressive form of brain cancer as researchers strive to find effective solutions against recurrent glioblastoma.

What are the most recent clinical trials for recurrent glioblastoma?

Exciting advancements in the field of recurrent glioblastoma research bring new possibilities for patients grappling with this challenging condition. Prominent among these clinical trials is Arm A, a Phase 2 study evaluating the efficacy of autologous treatment specifically designed for recurrent glioblastoma. Additionally, Group A's dose escalation trial aims to explore novel approaches to combat this aggressive form of brain cancer. Another Phase 1 study focuses on participants newly diagnosed with glioblastoma, seeking to understand and address its recurrence patterns. Stratum A enrolls 40 individuals as part of a Phase 2 trial investigating potential treatments for recurrent glioblastoma. Lastly, a groundbreaking Phase 1 trial explores combining standard surgical procedures with intraoperative electrocorticography—an innovative technique that holds promise for managing recurrent glioblastoma cases effectively. These compelling studies inspire hope and serve as beacons on the path towards improved outcomes for those affected by recurrent glioblastoma

What recurrent glioblastoma clinical trials were recently completed?

In the realm of recurrent glioblastoma, several clinical trials have recently concluded, signifying significant strides in understanding and treating this challenging disease. Notable completed trials include Tadalafil's trial from Washington University School of Medicine in May 2021 and Lidocaine's trial led by Kiarash Shahlaie, M.D., Ph.D., in January 2021. Additionally, GLR2007 sponsored by Gan and Lee Pharmaceuticals reached completion in July 2020. These advancements highlight the dedication of researchers and offer hope to patients grappling with recurrent glioblastoma.